1. Home
  2. NUW vs CABA Comparison

NUW vs CABA Comparison

Compare NUW & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen AMT-Free Municipal Value Fund

NUW

Nuveen AMT-Free Municipal Value Fund

N/A

Current Price

$14.41

Market Cap

256.9M

Sector

Finance

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

N/A

Current Price

$2.15

Market Cap

210.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUW
CABA
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
256.9M
210.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NUW
CABA
Price
$14.41
$2.15
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
45.3K
1.8M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
3.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.45
$0.99
52 Week High
$14.44
$3.67

Technical Indicators

Market Signals
Indicator
NUW
CABA
Relative Strength Index (RSI) 58.74 43.49
Support Level $14.30 $2.00
Resistance Level $14.43 $2.23
Average True Range (ATR) 0.11 0.13
MACD 0.01 -0.01
Stochastic Oscillator 95.00 29.59

Price Performance

Historical Comparison
NUW
CABA

About NUW Nuveen AMT-Free Municipal Value Fund

Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: